Jha Narendra N, Kim Jeong-Ki, Monani Umrao R
Department of Pathology & Cell Biology, 630 W. 168 St., Columbia University Medical Center, New York, NY 10032.
Center for Motor Neuron Biology & Disease, 630 W. 168 St., Columbia University Medical Center, New York, NY 10032.
Future Neurol. 2018 Aug;13(3):161-172. doi: 10.2217/fnl-2018-0008. Epub 2018 Jul 6.
Infantile-onset spinal muscular atrophy (SMA) is a prototypical disease in which to investigate selective neurodegenerative phenotypes. Caused by low levels of the ubiquitously expressed Survival Motor Neuron (SMN) protein, the disease mainly targets the spinal motor neurons. This selective phenotype remains largely unexplained, but has not hindered the development of SMN repletion as a means to a treatment. Here we chronicle recent advances in the area of SMA biology. We provide a brief background to the disease, highlight major advances that have shaped our current understanding of SMA, trace efforts to treat the condition, discuss the outcome of two promising new therapies and conclude by considering contemporary as well as new challenges stemming from recent successes within the field.
婴儿型脊髓性肌萎缩症(SMA)是一种典型疾病,可用于研究选择性神经退行性表型。该疾病由普遍表达的生存运动神经元(SMN)蛋白水平低下引起,主要影响脊髓运动神经元。这种选择性表型在很大程度上仍无法解释,但并未阻碍通过补充SMN进行治疗的发展。在此,我们记述SMA生物学领域的最新进展。我们简要介绍该疾病的背景,突出那些塑造了我们目前对SMA理解的重大进展,追溯治疗该病的努力,讨论两种有前景的新疗法的结果,并通过思考该领域近期成功带来的当代及新挑战来进行总结。